




**Figure S1.** (A) *Ccn1*<sup>WT/WT</sup> liver macrophages isolated 48 hrs after injection of vehicle or CCl<sub>4</sub> were cultured overnight and stained with anti-CD68 and anti-F4/80 antibodies and counterstained with DAPI. (B) *Ccn1*<sup>WT/WT</sup> liver macrophages isolated 48 hrs after injection of vehicle were co-stained with anti-CD206 antibody and anti-Galectin-3 antibody or anti-CD206 antibody and anti-CD11b antibody. The percentages of positive cells were quantified ( $n=4$ ). Data represents means  $\pm$  SD. Scale bars: 100  $\mu$ m.




**Figure S2.** *Ccn1*<sup>WT/WT</sup> and *Ccn1*<sup>D125A/D125A</sup> mice were i.p. injected with CCl<sub>4</sub>, and *Ccn1* (A) or *Ccn2* (B) expression was analyzed by qRT-PCR in liver RNA isolated at the indicated times ( $n=6$ ). (C) Liver sections from *Ccn1*<sup>WT/WT</sup> and *Ccn1*<sup>D125A/D125A</sup> mice after injection with CCl<sub>4</sub> for indicated times were stained with anti-CCN1 antibody. (D) Immunoblots of protein extracts from the indicated livers were probed with antibodies against CCN1 and  $\beta$ -actin. Scale bars: 100  $\mu$ m.




**Figure S3.** (A) Liver sections from *Ccn1*<sup>WT/WT</sup> and *Ccn1*<sup>D125A/D125A</sup> mice fed DDC diet for 4 weeks or subjected to BDL 7 days were immunostained for  $\alpha$ -smooth muscle actin ( $\alpha$ SMA, green) and counterstained with DAPI ( $n=6$ ) or stained with Sirius Red to reveal collagen deposition. The fibrotic areas were measured by Image J. The percentages of fibrotic areas were assessed by Image J analysis of microphotographs of six randomly selected fields. (B) Expression of *Tgfb1* in *Ccn1*<sup>WT/WT</sup> and *Ccn1*<sup>D125A/D125A</sup> mice livers which were subjected to BDL for 7 days was assessed by qRT-PCR ( $n=4$ ). . Data represent means  $\pm$  SD. \* $P<0.033$ , \*\* $P<0.002$ . Scale bars: 100  $\mu$ m.





**Figure S4.** (A) Serum ALT levels were measured 48 hrs after CCl<sub>4</sub> injection ( $n=6$ ). (B) Macrophages were isolated from injured livers and expression of indicated genes was assessed by qRT-PCR ( $n=6$ ). . Data represents means  $\pm$  SD. \* $P<0.033$ .



**Figure S5.** (A)  $Ccn1^{D125A/D125A}$  mice were injected with  $\text{CCl}_4$ , followed by *i.p.* injections of either vehicle or CCN1 protein (1 mg/kg) at 4, 24, and 40 hrs thereafter. Livers were collected at 48 hrs after  $\text{CCl}_4$  injection, and liver sections were stained with anti-Ly6G or anti-MPO antibody as indicated and counterstained with hematoxylin (blue). (B)  $Ccn1^{WT/WT}$  and  $Ccn1^{D125A/D125A}$  hepatic macrophages isolated 48 hrs after injection of  $\text{CCl}_4$  were co-stained with CD206 and Galectin-3 or CD206 and CD11b. The percentages of positive cells were quantified ( $n=4$ ). \* $P < 0.033$ , \*\* $P < 0.002$ , \*\*\* $P < 0.001$ . Data represents means  $\pm$  SD. Scale bars: 100  $\mu\text{m}$ .



**Figure S6.** Bone marrow derived macrophages (BMMs) from *Ccn1*<sup>WT/WT</sup> and *Ccn1*<sup>D125A/D125A</sup> mice were incubated for 4 hrs with their own apoptotic neutrophils, which were pre-treated with their own type of CCN1. (A) The expression of *cd206* and *Tgfb1* were assessed by qRT-PCR ( $n=4$ ). (B) HSCs isolated from uninjured *Ccn1*<sup>WT/WT</sup> and *Ccn1*<sup>D125A/D125A</sup> mice were co-cultured for 5 days with BMMs from *Ccn1*<sup>WT/WT</sup> and *Ccn1*<sup>D125A/D125A</sup> mice with or without apoptotic PMN and stained with anti- $\alpha$ SMA antibody. (C) The expression of  $\alpha$ SMA was assessed by qRT-PCR ( $n=4$ ). Data represents means  $\pm$  SD. \* $P<0.033$ , \*\* $P<0.002$ . Scale bars: 100  $\mu$ m.



**Figure S7.** HSCs isolated from *Ccn1*<sup>WT/WT</sup> mice 48 hrs after injection with CCl<sub>4</sub> were grown in culture. (A) Integrin  $\alpha_6$  mRNAs level and (B) Integrin  $\alpha_v$  mRNAs level were measured by qRT-PCR ( $n=4$ ). Data represents means  $\pm$  SD.

Gene	Orientation	Sequence (5' to 3')
<i><math>\alpha</math>SMA</i>	sense	ctgacagaggcaccactgaa
	antisense	gaaggaatagccacgctcag
<i>Tgf<math>\beta</math>1</i>	sense	gttttgaccccgaggagc
	antisense	gagaagagagcgcagaatcca
<i>Ccn1</i>	sense	ggaactggcatctccaca
	antisense	ttgggccgggtatttctt
<i>Ccn2</i>	sense	taggccctcagcctcact
	antisense	cttgacaggcttggggat
<i>Cyclophilin</i>	sense	ttcacaaccacaatggcacaggg
	antisense	tgccgtccagccaatctgtcttat
<i>Col1a1</i>	sense	ccaagggtaacagcggtgaa
	antisense	cctcgtttccttctctccg
<i>Mmp2</i>	sense	taacctggatgccgtcgt
	antisense	ttcaggaataagcacccttgaa
<i>Mmp9</i>	sense	cgtcgtgatcccacttact
	antisense	aacacacagggttgccttc
<i>Mmp13</i>	sense	agttgacaggctccgagaaa
	antisense	ggcactccacatcctggttt
<i>Pdgfa</i>	sense	gtgcgacctccaacctga
	antisense	ggctcatctcacctcacatct
<i>Pdgf<math>\beta</math></i>	sense	cggcctgtgactagaagtc
	antisense	gagcttgaggcgtcttgg
<i>Egf</i>	sense	agaaacaccaagacccaag
	antisense	tgtgccattccatctatgtg
<i>Igf</i>	sense	accgaggggcttttacttca
	antisense	tggctcaccttctctctcc

Table S1. Primer sequences used in this study.



Elisa kit	Company and catalog number
TGF- $\beta$ 1	BioLegend (436707)
Free active TGF- $\beta$ 1	BioLegend (437707)

Table S2. Elisa kits used in this study.

Antibody	dilution	Company and catalog number
$\alpha$ -SMA	1:200	abcam (ab7817)
Ly6G	1:300	BD pharmigen (551460)
Cleaved-Caspase3	1:300	Cell signaling (9661S)
CD206	1:500	Cell signaling (24595T)
Galectin-3	1:300	Cell signaling (89572S)
CD11b	1:300	Cell signaling (17800S)
F4/80	1:300	Bio-Rad (MCA497RT)
MPO	1:150	invitrogen (PA5-16672)
CD68	1:200	Abcam (ab53444)

Table S3. Antibodies used in staining.

Antibody	dilution	Company and catalog number
Anti-Phospho-Smad2	1:1000	Cell signaling (18338)
anti-Smad2	1:1000	Cell signaling (5339)
anti-CCN1	1:800	R&D Systems (AF4055)
anti- $\beta$ -actin	1:20000	Abcam (ab8226)

Table S4. Antibodies used in Western blots